Avalo Therapeutics appoints Dr. June Almenoff and Mitchell Chan as independent directors

Avalo Therapeutics, Inc.

Dr. June Almenoff appointed effective Nov 10, 2021; replaces Dr. Suzanne Bruhn.
Mitchell Chan appointed effective Dec 1, 2021; replaces Philip Gutry per Armistice Capital agreement.
Dr. Almenoff is CMO at RedHill Biopharma, ex-CMO of Furiex (acquired by Actavis), and former GSK executive.
Mr. Chan ex-CFO of Viela Bio (led $750M+ capital raises and $3.1B Horizon acquisition), prior roles at AstraZeneca and Genentech-Roche.
Chan will chair Audit Committee and serve on Compensation Committee; both are independent directors.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Philip Gutry

Director

AVTX · Avalo Therapeutics, Inc.

Effective: 2021-12-01
Successor: Mitchell Chan
Filed: December 6, 2021, 6:59 PM ET

As previously reported, pursuant to the Agreement, Mr. Philip Gutry’s resignation from the Board became effective on the date of Mr. Chan’s appointment to the Board.

Appointed

Mitchell Chan

Director

AVTX · Avalo Therapeutics, Inc.

Effective: 2021-12-01
Filed: December 6, 2021, 6:59 PM ET

On December 1, 2021, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Mitchell Chan, to the Board, effective immediately, pursuant to the terms of that certain Cooperation Agreement, dated as of November 4, 2021, with Armistice Capital, LLC (“ Agreement ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Philip Gutry resigned as Director at Avalo Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

As previously reported, pursuant to the Agreement, Mr. Philip Gutry’s resignation from the Board became effective on the date of Mr. Chan’s appointment to the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mitchell Chan was appointed as Director at Avalo Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 1, 2021, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Mitchell Chan, to the Board, effective immediately, pursuant to the terms of that certain Cooperation Agreement, dated as of November 4, 2021, with Armistice Capital, LLC (“ Agreement ”).

View on SEC.gov

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-21-024551

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.